Rheumatoid Arthritis

Key clinical point: Upadacitinib alone or in combination with methotrexate inhibits structural joint damage progression over a year in patients with rheumatoid arthritis (RA).

Major finding: The mean change in modified total Sharp score (mTSS) at 1 year for 15 mg upadacitinib and 30 mg upadacitinib vs. methotrexate was 0.03 and 0.14 vs. 1.00 (all P < .001). In methotrexate-inadequate responders (IR), mean change in mTSS with 15 mg upadacitinib vs. placebo (both with background methotrexate) was 0.28 vs. 1.73 (P < .001).

Study details: This was an analysis of 2 phase 3 trials involving patients with active RA who were either methotrexate-naive (SELECT-EARLY) and were randomly assigned to methotrexate monotherapy, 15 mg upadacitinib, or 30 mg upadacitinib or were methotrexate-IR (SELECT-COMPARE) and were randomly assigned to either 15 mg upadacitinib, 40 mg adalimumab, or placebo, all with background methotrexate.

Disclosures: This study was funded by AbbVie. IH Song, A Friedman, T Shaw, Y Li, S Chen, and JV Enejosa reported being full-time employees or owning stocks/stock options of AbbVie, and others reported receiving research grants and consultancy or speakers fees from various sources including AbbVie.

Source: Peterfy CG et al. Rheumatology (Oxford). 2021;keab861 (Dec 13). Doi:  10.1093/rheumatology/keab861.

Key clinical point: Upadacitinib alone or in combination with methotrexate inhibits structural joint damage progression over a year in patients with rheumatoid arthritis (RA).

Major finding: The mean change in modified total Sharp score (mTSS) at 1 year for 15 mg upadacitinib and 30 mg upadacitinib vs. methotrexate was 0.03 and 0.14 vs. 1.00 (all P < .001). In methotrexate-inadequate responders (IR), mean change in mTSS with 15 mg upadacitinib vs. placebo (both with background methotrexate) was 0.28 vs. 1.73 (P < .001).

Study details: This was an analysis of 2 phase 3 trials involving patients with active RA who were either methotrexate-naive (SELECT-EARLY) and were randomly assigned to methotrexate monotherapy, 15 mg upadacitinib, or 30 mg upadacitinib or were methotrexate-IR (SELECT-COMPARE) and were randomly assigned to either 15 mg upadacitinib, 40 mg adalimumab, or placebo, all with background methotrexate.

Disclosures: This study was funded by AbbVie. IH Song, A Friedman, T Shaw, Y Li, S Chen, and JV Enejosa reported being full-time employees or owning stocks/stock options of AbbVie, and others reported receiving research grants and consultancy or speakers fees from various sources including AbbVie.

Source: Peterfy CG et al. Rheumatology (Oxford). 2021;keab861 (Dec 13). Doi:  10.1093/rheumatology/keab861.

Key clinical point: Upadacitinib alone or in combination with methotrexate inhibits structural joint damage progression over a year in patients with rheumatoid arthritis (RA).

Major finding: The mean change in modified total Sharp score (mTSS) at 1 year for 15 mg upadacitinib and 30 mg upadacitinib vs. methotrexate was 0.03 and 0.14 vs. 1.00 (all P < .001). In methotrexate-inadequate responders (IR), mean change in mTSS with 15 mg upadacitinib vs. placebo (both with background methotrexate) was 0.28 vs. 1.73 (P < .001).

Study details: This was an analysis of 2 phase 3 trials involving patients with active RA who were either methotrexate-naive (SELECT-EARLY) and were randomly assigned to methotrexate monotherapy, 15 mg upadacitinib, or 30 mg upadacitinib or were methotrexate-IR (SELECT-COMPARE) and were randomly assigned to either 15 mg upadacitinib, 40 mg adalimumab, or placebo, all with background methotrexate.

Disclosures: This study was funded by AbbVie. IH Song, A Friedman, T Shaw, Y Li, S Chen, and JV Enejosa reported being full-time employees or owning stocks/stock options of AbbVie, and others reported receiving research grants and consultancy or speakers fees from various sources including AbbVie.

Source: Peterfy CG et al. Rheumatology (Oxford). 2021;keab861 (Dec 13). Doi:  10.1093/rheumatology/keab861.

Key clinical point: Upadacitinib alone or in combination with methotrexate inhibits structural joint damage progression over a year in patients with rheumatoid arthritis (RA).

Major finding: The mean change in modified total Sharp score (mTSS) at 1 year for 15 mg upadacitinib and 30 mg upadacitinib vs. methotrexate was 0.03 and 0.14 vs. 1.00 (all P < .001). In methotrexate-inadequate responders (IR), mean change in mTSS with 15 mg upadacitinib vs. placebo (both with background methotrexate) was 0.28 vs. 1.73 (P < .001).

Study details: This was an analysis of 2 phase 3 trials involving patients with active RA who were either methotrexate-naive (SELECT-EARLY) and were randomly assigned to methotrexate monotherapy, 15 mg upadacitinib, or 30 mg upadacitinib or were methotrexate-IR (SELECT-COMPARE) and were randomly assigned to either 15 mg upadacitinib, 40 mg adalimumab, or placebo, all with background methotrexate.

Disclosures: This study was funded by AbbVie. IH Song, A Friedman, T Shaw, Y Li, S Chen, and JV Enejosa reported being full-time employees or owning stocks/stock options of AbbVie, and others reported receiving research grants and consultancy or speakers fees from various sources including AbbVie.

Source: Peterfy CG et al. Rheumatology (Oxford). 2021;keab861 (Dec 13). Doi:  10.1093/rheumatology/keab861.

Key clinical point: Upadacitinib alone or in combination with methotrexate inhibits structural joint damage progression over a year in patients with rheumatoid arthritis (RA).

Major finding: The mean change in modified total Sharp score (mTSS) at 1 year for 15 mg upadacitinib and 30 mg upadacitinib vs. methotrexate was 0.03 and 0.14 vs. 1.00 (all P < .001). In methotrexate-inadequate responders (IR), mean change in mTSS with 15 mg upadacitinib vs. placebo (both with background methotrexate) was 0.28 vs. 1.73 (P < .001).

Study details: This was an analysis of 2 phase 3 trials involving patients with active RA who were either methotrexate-naive (SELECT-EARLY) and were randomly assigned to methotrexate monotherapy, 15 mg upadacitinib, or 30 mg upadacitinib or were methotrexate-IR (SELECT-COMPARE) and were randomly assigned to either 15 mg upadacitinib, 40 mg adalimumab, or placebo, all with background methotrexate.

Disclosures: This study was funded by AbbVie. IH Song, A Friedman, T Shaw, Y Li, S Chen, and JV Enejosa reported being full-time employees or owning stocks/stock options of AbbVie, and others reported receiving research grants and consultancy or speakers fees from various sources including AbbVie.

Source: Peterfy CG et al. Rheumatology (Oxford). 2021;keab861 (Dec 13). Doi:  10.1093/rheumatology/keab861.

Key clinical point: Upadacitinib alone or in combination with methotrexate inhibits structural joint damage progression over a year in patients with rheumatoid arthritis (RA).

Major finding: The mean change in modified total Sharp score (mTSS) at 1 year for 15 mg upadacitinib and 30 mg upadacitinib vs. methotrexate was 0.03 and 0.14 vs. 1.00 (all P < .001). In methotrexate-inadequate responders (IR), mean change in mTSS with 15 mg upadacitinib vs. placebo (both with background methotrexate) was 0.28 vs. 1.73 (P < .001).

Study details: This was an analysis of 2 phase 3 trials involving patients with active RA who were either methotrexate-naive (SELECT-EARLY) and were randomly assigned to methotrexate monotherapy, 15 mg upadacitinib, or 30 mg upadacitinib or were methotrexate-IR (SELECT-COMPARE) and were randomly assigned to either 15 mg upadacitinib, 40 mg adalimumab, or placebo, all with background methotrexate.

Disclosures: This study was funded by AbbVie. IH Song, A Friedman, T Shaw, Y Li, S Chen, and JV Enejosa reported being full-time employees or owning stocks/stock options of AbbVie, and others reported receiving research grants and consultancy or speakers fees from various sources including AbbVie.

Source: Peterfy CG et al. Rheumatology (Oxford). 2021;keab861 (Dec 13). Doi:  10.1093/rheumatology/keab861.

Key clinical point: A clinically noteworthy improvement in mental health was observed in patients with rheumatoid arthritis (RA) who were treated with Janus kinase (JAK) inhibitors.

Major finding: The pooled incremental mean reduction in short form-36 mental component score with JAK monotherapy was 4.95 (95% CI 4.41-5.48), which was greater than the minimum clinically important difference value of 2.5, indicating significant improvement in mental health following JAK monotherapy.

Study details: This was a meta-analysis of 19 studies involving 14,323 patients with RA.

Disclosures: This study received no specific funding. The authors did not have any potential conflict of interests.

Source: Shamail GMH et al. Rheumatol Ther. 2021 (Dec 13). Doi: 10.1007/s40744-021-00409-6.

Key clinical point: A clinically noteworthy improvement in mental health was observed in patients with rheumatoid arthritis (RA) who were treated with Janus kinase (JAK) inhibitors.

Major finding: The pooled incremental mean reduction in short form-36 mental component score with JAK monotherapy was 4.95 (95% CI 4.41-5.48), which was greater than the minimum clinically important difference value of 2.5, indicating significant improvement in mental health following JAK monotherapy.

Study details: This was a meta-analysis of 19 studies involving 14,323 patients with RA.

Disclosures: This study received no specific funding. The authors did not have any potential conflict of interests.

Source: Shamail GMH et al. Rheumatol Ther. 2021 (Dec 13). Doi: 10.1007/s40744-021-00409-6.

Key clinical point: A clinically noteworthy improvement in mental health was observed in patients with rheumatoid arthritis (RA) who were treated with Janus kinase (JAK) inhibitors.

Major finding: The pooled incremental mean reduction in short form-36 mental component score with JAK monotherapy was 4.95 (95% CI 4.41-5.48), which was greater than the minimum clinically important difference value of 2.5, indicating significant improvement in mental health following JAK monotherapy.

Study details: This was a meta-analysis of 19 studies involving 14,323 patients with RA.

Disclosures: This study received no specific funding. The authors did not have any potential conflict of interests.

Source: Shamail GMH et al. Rheumatol Ther. 2021 (Dec 13). Doi: 10.1007/s40744-021-00409-6.

Key clinical point: In a cohort of patients with early rheumatoid arthritis (RA), illness perceptions and suboptimal psychosocial well-being were associated with a lower likelihood of sustained remission.

Major finding: Among patients who were had a disease activity score in 28 joints-C-reactive protein remission at week 16, those with a low vs. high psychosocial burden profile showed a significantly longer time to first loss-of-remission (hazard ratio 0.51; P < .001).

Study details: This was a post hoc analysis of the CareRA trial involving 379 patients with early RA who received methotrexate ± additional conventional synthetic disease-modifying antirheumatic drugs or glucocorticoids.

Disclosures: This study was supported in part by a Strategic Basic Research Fellowship grant from Fonds Wetenschappelijk Onderzoek. All the authors declared no conflicts of interest.

Source: Doumen M et al. Arthritis Care Res (Hoboken). 2021 (Dec 20). Doi: 10.1002/acr.24847.

Key clinical point: In a cohort of patients with early rheumatoid arthritis (RA), illness perceptions and suboptimal psychosocial well-being were associated with a lower likelihood of sustained remission.

Major finding: Among patients who were had a disease activity score in 28 joints-C-reactive protein remission at week 16, those with a low vs. high psychosocial burden profile showed a significantly longer time to first loss-of-remission (hazard ratio 0.51; P < .001).

Study details: This was a post hoc analysis of the CareRA trial involving 379 patients with early RA who received methotrexate ± additional conventional synthetic disease-modifying antirheumatic drugs or glucocorticoids.

Disclosures: This study was supported in part by a Strategic Basic Research Fellowship grant from Fonds Wetenschappelijk Onderzoek. All the authors declared no conflicts of interest.

Source: Doumen M et al. Arthritis Care Res (Hoboken). 2021 (Dec 20). Doi: 10.1002/acr.24847.

Key clinical point: In a cohort of patients with early rheumatoid arthritis (RA), illness perceptions and suboptimal psychosocial well-being were associated with a lower likelihood of sustained remission.

Major finding: Among patients who were had a disease activity score in 28 joints-C-reactive protein remission at week 16, those with a low vs. high psychosocial burden profile showed a significantly longer time to first loss-of-remission (hazard ratio 0.51; P < .001).

Study details: This was a post hoc analysis of the CareRA trial involving 379 patients with early RA who received methotrexate ± additional conventional synthetic disease-modifying antirheumatic drugs or glucocorticoids.

Disclosures: This study was supported in part by a Strategic Basic Research Fellowship grant from Fonds Wetenschappelijk Onderzoek. All the authors declared no conflicts of interest.

Source: Doumen M et al. Arthritis Care Res (Hoboken). 2021 (Dec 20). Doi: 10.1002/acr.24847.

Key clinical point: Celecoxib appeared to be relatively safer compared with nonselective nonsteroidal anti-inflammatory drugs (NSAID) or placebo in patients with rheumatoid arthritis (RA), regardless of dose or duration.

Major finding: Celecoxib was associated with a lower risk for all-cause mortality (risk ratio [RR] 0.81; 95% CI 0.66-0.98) and cardiovascular morality (RR 0.75; 95% CI 0.57-0.99) compared with NSAIDs and a similar risk for all-cause mortality (RR 0.92; 95% CI 0.26-3.27) and cardiovascular morality (RR 3.02; 95% CI 0.36-25.27) compared with placebo.

Study details: Findings are from a meta-analysis of 21 randomized clinical studies that compared cardiovascular safety of celecoxib with NSAIDs or placebo in patients with RA or osteoarthritis.

Disclosures: This study was supported by the National Natural Science Foundation project and others. No competing interests were declared.

Source: Cheng BR et al. PLoS One. 2021;16(12):e0261239 (Dec 21). Doi:  10.1371/journal.pone.0261239.

Key clinical point: Celecoxib appeared to be relatively safer compared with nonselective nonsteroidal anti-inflammatory drugs (NSAID) or placebo in patients with rheumatoid arthritis (RA), regardless of dose or duration.

Major finding: Celecoxib was associated with a lower risk for all-cause mortality (risk ratio [RR] 0.81; 95% CI 0.66-0.98) and cardiovascular morality (RR 0.75; 95% CI 0.57-0.99) compared with NSAIDs and a similar risk for all-cause mortality (RR 0.92; 95% CI 0.26-3.27) and cardiovascular morality (RR 3.02; 95% CI 0.36-25.27) compared with placebo.

Study details: Findings are from a meta-analysis of 21 randomized clinical studies that compared cardiovascular safety of celecoxib with NSAIDs or placebo in patients with RA or osteoarthritis.

Disclosures: This study was supported by the National Natural Science Foundation project and others. No competing interests were declared.

Source: Cheng BR et al. PLoS One. 2021;16(12):e0261239 (Dec 21). Doi:  10.1371/journal.pone.0261239.

Key clinical point: Celecoxib appeared to be relatively safer compared with nonselective nonsteroidal anti-inflammatory drugs (NSAID) or placebo in patients with rheumatoid arthritis (RA), regardless of dose or duration.

Major finding: Celecoxib was associated with a lower risk for all-cause mortality (risk ratio [RR] 0.81; 95% CI 0.66-0.98) and cardiovascular morality (RR 0.75; 95% CI 0.57-0.99) compared with NSAIDs and a similar risk for all-cause mortality (RR 0.92; 95% CI 0.26-3.27) and cardiovascular morality (RR 3.02; 95% CI 0.36-25.27) compared with placebo.

Study details: Findings are from a meta-analysis of 21 randomized clinical studies that compared cardiovascular safety of celecoxib with NSAIDs or placebo in patients with RA or osteoarthritis.

Disclosures: This study was supported by the National Natural Science Foundation project and others. No competing interests were declared.

Source: Cheng BR et al. PLoS One. 2021;16(12):e0261239 (Dec 21). Doi:  10.1371/journal.pone.0261239.

Key clinical point: Patients with rheumatoid arthritis (RA) experienced robust pain reduction with baricitinib, irrespective of opioid use.

Major finding: Compared with placebo, pain reduction was significantly greater at all time points, starting as early as week 1 (all P < .05) in both opioid users and nonusers receiving 4 mg baricitinib and only in opioid users receiving 2 mg baricitinib. Opioid nonusers receiving 2 mg baricitinib showed greater pain relief than placebo starting at week 4 (P < .05).

Study details: This was a post hoc analysis of 3 randomized controlled trials (RA-BEAM, RA-BUILD, and RA-BEACON) involving patients with RA with an inadequate response to either methotrexate, conventional disease-modifying antirheumatic drugs, or at least 1 tumor necrosis factor inhibitor, who were randomly assigned to either placebo, baricitinib (2 mg/4 mg), or adalimumab (40 mg) in addition to background therapy.

Disclosures: This study was funded by Eli Lilly under license from Incyte Corporation. The authors declared no conflict of interests.

Source: Pope JE et al. ACR Open Rheumatol. 2021 (Dec 16). Doi: 10.1002/acr2.11380.

Key clinical point: Patients with rheumatoid arthritis (RA) experienced robust pain reduction with baricitinib, irrespective of opioid use.

Major finding: Compared with placebo, pain reduction was significantly greater at all time points, starting as early as week 1 (all P < .05) in both opioid users and nonusers receiving 4 mg baricitinib and only in opioid users receiving 2 mg baricitinib. Opioid nonusers receiving 2 mg baricitinib showed greater pain relief than placebo starting at week 4 (P < .05).

Study details: This was a post hoc analysis of 3 randomized controlled trials (RA-BEAM, RA-BUILD, and RA-BEACON) involving patients with RA with an inadequate response to either methotrexate, conventional disease-modifying antirheumatic drugs, or at least 1 tumor necrosis factor inhibitor, who were randomly assigned to either placebo, baricitinib (2 mg/4 mg), or adalimumab (40 mg) in addition to background therapy.

Disclosures: This study was funded by Eli Lilly under license from Incyte Corporation. The authors declared no conflict of interests.

Source: Pope JE et al. ACR Open Rheumatol. 2021 (Dec 16). Doi: 10.1002/acr2.11380.

Key clinical point: Patients with rheumatoid arthritis (RA) experienced robust pain reduction with baricitinib, irrespective of opioid use.

Major finding: Compared with placebo, pain reduction was significantly greater at all time points, starting as early as week 1 (all P < .05) in both opioid users and nonusers receiving 4 mg baricitinib and only in opioid users receiving 2 mg baricitinib. Opioid nonusers receiving 2 mg baricitinib showed greater pain relief than placebo starting at week 4 (P < .05).

Study details: This was a post hoc analysis of 3 randomized controlled trials (RA-BEAM, RA-BUILD, and RA-BEACON) involving patients with RA with an inadequate response to either methotrexate, conventional disease-modifying antirheumatic drugs, or at least 1 tumor necrosis factor inhibitor, who were randomly assigned to either placebo, baricitinib (2 mg/4 mg), or adalimumab (40 mg) in addition to background therapy.

Disclosures: This study was funded by Eli Lilly under license from Incyte Corporation. The authors declared no conflict of interests.

Source: Pope JE et al. ACR Open Rheumatol. 2021 (Dec 16). Doi: 10.1002/acr2.11380.

Key clinical point: Significant improvement in patient-reported outcomes was observed with filgotinib in patients with rheumatoid arthritis (RA) with an insufficient response to methotrexate or biological disease-modifying antirheumatic drugs (DMARD) and those who were methotrexate-naive.

Major finding: Filgotinib at doses of 200 mg or 100 mg in combination with methotrexate/conventional synthetic DMARDs or 200 mg filgotinib monotherapy demonstrated a significant improvement in the health-related quality of life, fatigue, and assessments of disease activity and work impairment vs. comparators (all P < .05).

Study details: This was a post hoc analysis of phase 3 studies including patients with RA with an inadequate response to methotrexate (FINCH 1) or biological DMARDs (FINCH 2) and those who were methotrexate-naive (FINCH 3).

Disclosures: This study was supported by Gilead Sciences, Inc., Foster City, CA. SJ Lee, L Ye, and H Hu reported being employees and shareholders of Gilead Sciences. All the other authors disclosed receiving grants/research support and speaker/consultancy fees from various companies including Gilead Sciences.

Source: Bingham CO III et al. Arthritis Res Ther. 2022;24:11 (Jan 3). Doi: 10.1186/s13075-021-02677-7.

Key clinical point: Significant improvement in patient-reported outcomes was observed with filgotinib in patients with rheumatoid arthritis (RA) with an insufficient response to methotrexate or biological disease-modifying antirheumatic drugs (DMARD) and those who were methotrexate-naive.

Major finding: Filgotinib at doses of 200 mg or 100 mg in combination with methotrexate/conventional synthetic DMARDs or 200 mg filgotinib monotherapy demonstrated a significant improvement in the health-related quality of life, fatigue, and assessments of disease activity and work impairment vs. comparators (all P < .05).

Study details: This was a post hoc analysis of phase 3 studies including patients with RA with an inadequate response to methotrexate (FINCH 1) or biological DMARDs (FINCH 2) and those who were methotrexate-naive (FINCH 3).

Disclosures: This study was supported by Gilead Sciences, Inc., Foster City, CA. SJ Lee, L Ye, and H Hu reported being employees and shareholders of Gilead Sciences. All the other authors disclosed receiving grants/research support and speaker/consultancy fees from various companies including Gilead Sciences.

Source: Bingham CO III et al. Arthritis Res Ther. 2022;24:11 (Jan 3). Doi: 10.1186/s13075-021-02677-7.

Key clinical point: Significant improvement in patient-reported outcomes was observed with filgotinib in patients with rheumatoid arthritis (RA) with an insufficient response to methotrexate or biological disease-modifying antirheumatic drugs (DMARD) and those who were methotrexate-naive.

Major finding: Filgotinib at doses of 200 mg or 100 mg in combination with methotrexate/conventional synthetic DMARDs or 200 mg filgotinib monotherapy demonstrated a significant improvement in the health-related quality of life, fatigue, and assessments of disease activity and work impairment vs. comparators (all P < .05).

Study details: This was a post hoc analysis of phase 3 studies including patients with RA with an inadequate response to methotrexate (FINCH 1) or biological DMARDs (FINCH 2) and those who were methotrexate-naive (FINCH 3).

Disclosures: This study was supported by Gilead Sciences, Inc., Foster City, CA. SJ Lee, L Ye, and H Hu reported being employees and shareholders of Gilead Sciences. All the other authors disclosed receiving grants/research support and speaker/consultancy fees from various companies including Gilead Sciences.

Source: Bingham CO III et al. Arthritis Res Ther. 2022;24:11 (Jan 3). Doi: 10.1186/s13075-021-02677-7.

Key clinical point: Every 1 in 6 individuals with rheumatoid arthritis (RA) develop interstitial lung disease (ILD) within 20 years, with RA-associated ILD (RA-ILD), even when asymptomatic and radiologically limited, being significantly associated with shorter survival.

Major finding: The cumulative incidence of RA-ILD was 15.3% at 20 years after RA diagnosis, with mortality being higher in patients with RA-ILD vs. matched RA comparators (hazard ratio 2.42; 95% CI 1.32-4.41).

Study details: This was a population-based cohort study involving 645 patients with incident RA.

Disclosures: This study was funded by the National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases, and others. R Vassallo and JM Davis III reported receiving research grants from various sources.

Source: Samhouri BF et al. Arthritis Care Res (Hoboken). 2022 (Jan 7). Doi: 10.1002/acr.24856.

Key clinical point: Every 1 in 6 individuals with rheumatoid arthritis (RA) develop interstitial lung disease (ILD) within 20 years, with RA-associated ILD (RA-ILD), even when asymptomatic and radiologically limited, being significantly associated with shorter survival.

Major finding: The cumulative incidence of RA-ILD was 15.3% at 20 years after RA diagnosis, with mortality being higher in patients with RA-ILD vs. matched RA comparators (hazard ratio 2.42; 95% CI 1.32-4.41).

Study details: This was a population-based cohort study involving 645 patients with incident RA.

Disclosures: This study was funded by the National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases, and others. R Vassallo and JM Davis III reported receiving research grants from various sources.

Source: Samhouri BF et al. Arthritis Care Res (Hoboken). 2022 (Jan 7). Doi: 10.1002/acr.24856.

Key clinical point: Every 1 in 6 individuals with rheumatoid arthritis (RA) develop interstitial lung disease (ILD) within 20 years, with RA-associated ILD (RA-ILD), even when asymptomatic and radiologically limited, being significantly associated with shorter survival.

Major finding: The cumulative incidence of RA-ILD was 15.3% at 20 years after RA diagnosis, with mortality being higher in patients with RA-ILD vs. matched RA comparators (hazard ratio 2.42; 95% CI 1.32-4.41).

Study details: This was a population-based cohort study involving 645 patients with incident RA.

Disclosures: This study was funded by the National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases, and others. R Vassallo and JM Davis III reported receiving research grants from various sources.

Source: Samhouri BF et al. Arthritis Care Res (Hoboken). 2022 (Jan 7). Doi: 10.1002/acr.24856.

Key clinical point: In patients with rheumatoid arthritis (RA), sleep problems are more extensively related to pain and functional impairment than disease duration.

Major finding: The likelihood of having problems with at least 1 or more sleep domains increased slightly with the disease duration (adjusted odds ratio 1.04; 95% CI 1.02-1.07). High-grade pain and high Health Assessment Questionnaire (HAQ) level were associated with increased sleep problems by approximately 3-9-fold and 4-8-fold compared with low-grade pain and low HAQ level, respectively.

Study details: This was an analysis of 4,131 observations from 3,265 patients with newly diagnosed RA whose data on sleep over 12 years from diagnosis were available.

Disclosures: This study was supported by Karolinska Institutet and Reumatikerförbundet. All the authors declared no competing interests.

Source: Lyne L et al. RMD Open. 2022;8:e001800 (Jan 5). Doi: 10.1136/rmdopen-2021-001800.

Key clinical point: In patients with rheumatoid arthritis (RA), sleep problems are more extensively related to pain and functional impairment than disease duration.

Major finding: The likelihood of having problems with at least 1 or more sleep domains increased slightly with the disease duration (adjusted odds ratio 1.04; 95% CI 1.02-1.07). High-grade pain and high Health Assessment Questionnaire (HAQ) level were associated with increased sleep problems by approximately 3-9-fold and 4-8-fold compared with low-grade pain and low HAQ level, respectively.

Study details: This was an analysis of 4,131 observations from 3,265 patients with newly diagnosed RA whose data on sleep over 12 years from diagnosis were available.

Disclosures: This study was supported by Karolinska Institutet and Reumatikerförbundet. All the authors declared no competing interests.

Source: Lyne L et al. RMD Open. 2022;8:e001800 (Jan 5). Doi: 10.1136/rmdopen-2021-001800.

Key clinical point: In patients with rheumatoid arthritis (RA), sleep problems are more extensively related to pain and functional impairment than disease duration.

Major finding: The likelihood of having problems with at least 1 or more sleep domains increased slightly with the disease duration (adjusted odds ratio 1.04; 95% CI 1.02-1.07). High-grade pain and high Health Assessment Questionnaire (HAQ) level were associated with increased sleep problems by approximately 3-9-fold and 4-8-fold compared with low-grade pain and low HAQ level, respectively.

Study details: This was an analysis of 4,131 observations from 3,265 patients with newly diagnosed RA whose data on sleep over 12 years from diagnosis were available.

Disclosures: This study was supported by Karolinska Institutet and Reumatikerförbundet. All the authors declared no competing interests.

Source: Lyne L et al. RMD Open. 2022;8:e001800 (Jan 5). Doi: 10.1136/rmdopen-2021-001800.

Key clinical point: Fatigue was prevalent and persistent in patients with early rheumatoid arthritis (RA) with female gender, poor mental health, pain, and some functional abilities associated with greater fatigue.

Major finding: The age- and sex-standardized prevalence of fatigue and severe fatigue was 44% (95% CI 39%-50%) and 19% (95% CI 15%-23%), respectively, with little change observed over 3 years (ß −0.13; 95% CI −0.23 to −0.02). Female gender, worse pain, mental health, and functional ability were significantly associated with greater fatigue (P ≤ .05).

Study details: This was a multicenter cohort study involving 729 patients with RA with symptom duration of <2 years.

Disclosures: This work was funded by the Versus Arthritis Pain Centre. DF McWilliams and DA Walsh reported receiving funding and consultancy fees from various sources.

Source: Ifesemen OS et al. Rheumatology (Oxford). 2021;keab861 (Dec 27). Doi:  10.1093/rheumatology/keab947.

Key clinical point: Fatigue was prevalent and persistent in patients with early rheumatoid arthritis (RA) with female gender, poor mental health, pain, and some functional abilities associated with greater fatigue.

Major finding: The age- and sex-standardized prevalence of fatigue and severe fatigue was 44% (95% CI 39%-50%) and 19% (95% CI 15%-23%), respectively, with little change observed over 3 years (ß −0.13; 95% CI −0.23 to −0.02). Female gender, worse pain, mental health, and functional ability were significantly associated with greater fatigue (P ≤ .05).

Study details: This was a multicenter cohort study involving 729 patients with RA with symptom duration of <2 years.

Disclosures: This work was funded by the Versus Arthritis Pain Centre. DF McWilliams and DA Walsh reported receiving funding and consultancy fees from various sources.

Source: Ifesemen OS et al. Rheumatology (Oxford). 2021;keab861 (Dec 27). Doi:  10.1093/rheumatology/keab947.

Key clinical point: Fatigue was prevalent and persistent in patients with early rheumatoid arthritis (RA) with female gender, poor mental health, pain, and some functional abilities associated with greater fatigue.

Major finding: The age- and sex-standardized prevalence of fatigue and severe fatigue was 44% (95% CI 39%-50%) and 19% (95% CI 15%-23%), respectively, with little change observed over 3 years (ß −0.13; 95% CI −0.23 to −0.02). Female gender, worse pain, mental health, and functional ability were significantly associated with greater fatigue (P ≤ .05).

Study details: This was a multicenter cohort study involving 729 patients with RA with symptom duration of <2 years.

Disclosures: This work was funded by the Versus Arthritis Pain Centre. DF McWilliams and DA Walsh reported receiving funding and consultancy fees from various sources.

Source: Ifesemen OS et al. Rheumatology (Oxford). 2021;keab861 (Dec 27). Doi:  10.1093/rheumatology/keab947.